SMC accepts Lumykras (sotorasib) for locally advanced or metastatic non-small cell lung cancer for use on an interim basis by NHS Scotland

Amgen

7 March 2022 - Sotorasib Is indicated as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small-cell lung cancer who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.

The SMC has today accepted Amgen’s first in class drug, Lumykras (sotorasib), for use on an interim basis by NHS Scotland as monotherapy for the treatment of adult patients with KRAS G12C mutated locally advanced or metastatic non-small-cell lung cancer, who have progressed on, or are intolerant to, platinum-based chemotherapy and/or anti PD-1/PD-L1 immunotherapy.

Read Amgen press release

Michael Wonder

Posted by:

Michael Wonder